Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, novembre 13
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Takeda Pharmaceutical Co Ltd
TAK
NYSE
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$21.43
0.31
1.47%
Dern. MÀJ: Nov 13, 11:36 AM
Get Report
Aperçu
Actualités
Graphiques
Prévisions de résultats
Événements
Données financières
Sentiment
Actionnariat
Dividendes
Comparer
Options
Rapport sur les stocks
Takeda Pharmaceutical Co Financials
Takeda Pharmaceutical Co (TAK) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Takeda Beats Earnings Forecasts and Hikes Outlook Despite Generic Overhang
Takeda Pharmaceutical (TAK) beats Q2 estimates and lifts fiscal 2026 guidance as pipeline growth and cost cuts balance off-patent Vyvanse losses.
Vandana Singh
PRO
Takeda Pharmaceutical Co Raises FY2026 Core EPS Guidance from JPY 472 to JPY 482; Raises FY2026 Revenue Guidance from JPY 4,640B to JPY 4,700B
Takeda Pharmaceutical Co (NYSE:TAK) Raises FY2026 Core EPS Guidance from JPY 472 to JPY 482; Raises FY2026 Revenue Guidance from JPY 4,640B to JPY 4,700B
Benzinga Newsdesk
PRO
Takeda Pharmaceutical Q2 Adj. EPS $0.48 Beats $0.31 Estimate, Sales $7.457B Beat $7.190B Estimate
Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.31 by 54.84 percent. This is a 20 percent increase over earnings of $0.40 per share from
Benzinga Newsdesk
PRO
Takeda Pharmaceutical Co Raises FY2026 GAAP EPS Guidance from JPY 104 to JPY 131
Takeda Pharmaceutical Co (NYSE:TAK) Raises FY2026 GAAP EPS Guidance from JPY 104 to JPY 131
Benzinga Newsdesk
PRO
CORRECTION: Takeda Pharmaceutical Co Affirms FY2026 Adj EPS Guidance of $3.01 vs $1.57 Est; Affirms FY2026 Sales Guidance of $29.585B vs $28.950B Est
Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 Adj EPS guidance from $3.01 to $3.01 vs $1.57 analyst estimate. Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion vs $28.950 billion estimate.
Benzinga Newsdesk
PRO
Takeda Pharmaceutical Co Affirms FY2026 GAAP EPS Guidance of $0.66; Affirms FY2026 GAAP Sales Guidance of $29.585B
Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 GAAP EPS guidance from $0.66 to $0.66. Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion.
Benzinga Newsdesk
